NCT01908400

Safety and Efficacy of BMMNCin Patients With Mental Retardation

An Open Labeled Clinical Study to Evaluate the Safety and Efficacy of Autologous Bone Marrow Derived Mono Nuclear Stem Cell (BMMNCs) in Patients With Mental Retardation. It is Self Funded (Patients' Own Funding) Clinical Trial

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 15 (estimated)
• Sponsor: Chaitanya Hospital, Pune · Academic / Other
• Sex: All
• Age: 5 Years – 50 Years
• Healthy volunteers: Accepted

Summary

Mental retardation is a condition diagnosed before age 18 that includes below-average general intellectual function, and a lack of the skills necessary for daily living. Mental retardation affects about 1 - 3% of the population. There are many causes of mental retardation, but find a specific reason in only 25% of cases.Bone marrow derived stem cells are used in this condition to prove its safety and efficacy .

Conditions

• Mental Retardation

Interventions

Type	Name	Description
BIOLOGICAL	Intravenous transfer of BMMNC	Intervention therapy , Total 3 doses ,in 30 days ,in 7days interval Intravenous transfer of Autologous Bone Marrow derived Mono Nuclear Stem Cell (BMMNCs)

Timeline

• Start date: 2014-09-01
• Primary completion: 2016-11-01
• Completion: 2016-11-01
• First posted: 2013-07-25
• Last updated: 2014-09-17

Locations

1 site across 1 country: India